In this engaging discussion, Ashwin Varma, a medical student at UT Health San Antonio with a focus on pharma business, delves into the fascinating history and innovation behind Merck & Co. They explore the pivotal role of Keytruda, a blockbuster cancer drug generating over $25 billion annually. Ashwin highlights Merck's strategic approach to drug development, the challenges of patent expirations, and the company's leadership transition. This conversation shines a light on the intersection of science, business, and the complex world of pharmaceuticals.
